Ecaterina E Dumbrava, M.D.

Peer-Reviewed Articles

1. Dumbrava EE, Olson D, Gouda MA, George MA, Saibil SD, Apostolopoulou M, Bishop M, Gavriliuc MN, Kennon AM, Weiss JA, Ayers C, Moss K, Helsen CW, Rill D, Bader AG, Adib D, Schlechter BL. Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors. Ann Oncol. e-Pub 2026. PMID: 42177028.
2. Torrado Martin C, Andersen C, Kang L, Brink AL, Adesoye T, Le H, Patterson CJ, Poullard, A, Osburn JA, Tan HN, Gouda M, Charles S, Urschel G, Tang T, Hong DS, Champiat S, Naing A, Tsimberidou AM, Dumbrava EE, Piha-Paul SA, Rodon Ahnert J, Yap TA, Pohlmann PR, Meric-Bernstam F, Fu S. Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41830429.
3. Venturini J, Baysal MA, Chakraborty A, Yap TA, Fu S, Hong DS, Piha-Paul SA, Naing A, Ahnert JR, Dumbrava EE, Beck J, Liu Y, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study. NPJ Precis Oncol, 2026. e-Pub 2026. PMID: 41963611.
4. Johnson A, Shen Y, Zheng X, Su F, Zeng J, Uzunparmak B, Breuer E, Holla V, Kahle M, Kim S, Vu T, Mills Shaw KR, Dumbrava, EE, Yap TA, Rodon Ahnert J, Routbort MJ, Patel KP, Kulkarni S, Hansel DE, Bryan J, Korkut A, Chen K, Meric-Bernstam F. The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology. Nature Reviews Clinical Oncology 23(3):213-229, 2026. e-Pub 2026. PMID: 41492079.
5. Uzunparmak B, Su F, Johnson A, Shaw KRM, Kong EK, Korkut A, Braganca Xavier C, Yuan Y, Fowler NH, Paradiso F, Kontselidze L, Butusova A, Bagaev A, Dumbrava EE, Rodon J, Hong DS, Yap TA, Fu S, Naing A, Piha-Paul SA, Ferrarotto R, Bryan J, Kulkarni S, Patel KP, Meric-Bernstam F. Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors. Cancer Discov, 2026. e-Pub 2026. PMID: 41885383.
6. Dumbrava E, Minchom A, Henry J, Johnson M, Sommerhalder D, Merchan J, Heist R, Cabanas EG, Cotreau M, Goenaga AL, Burzyn D, Makris L, Culm K, Abbadessa G. MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. Future Oncol 22(3):305-312, 2026. e-Pub 2026. PMID: 41495607.
7. Beckham TH, Dudzinski SO, Rooney MK, Faraj CA, Pasli M, Perni S, Tom M, Ghia A, Yeboa DN, McAleer MF, Swanson T, McGovern S, Wang C, Chung C, De B, Jiang W, Kim BYS, Ferguson SD, Tawbi HA, Glitza I, Le X, Kaya D, Dumbrava EE, Briere T, Mackin D, Li J. Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases. J Natl Compr Canc Netw 24(2):34-40, 2026. e-Pub 2026. PMID: 41671425.
8. Dumbrava EE, Shapiro GI, Parikh AR, Johnson M, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross A, Kummar S, Shepard D, LeDuke K, Sheehan L, Alland L, Haque A, Jalota D, Fellous M, Schram AM. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. N Engl J Med 394(9):872-883, 2026. e-Pub 2026. PMID: 41740031.
9. Schmidt ST, Baysal M, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Meric-Bernstam F, Tsimberidou AM. Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. Signal Transduct Target Ther 11(1):68, 2026. e-Pub 2026. PMID: 41730847.
10. Lim JU, Lin Y, Kang L, Le H, Tang T, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. NPJ Precis Oncol 10(1), 2026. e-Pub 2026. PMID: 41530472.
11. Schram AM, Park JJ, Italiano A, Kitano S, Guo Y, Li J, Bedard P, Van Marcke C, Ko R, Lunger L, Klotz DM, Hussain J, Maier D, Erzen D, Planchard D, Prenen H, Clay TD, Park JO, Kim HD, Hernando-Calvo A, Maruki Y, Ponz M, Dumbrava EE. Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncology 22(7):795-803, 2026. e-Pub 2026. PMID: 41777164.
12. Piha-Paul SA, Tseng C, Tran HT, Fu S, Dumbrava EE, Yap TA, Naing A, Lim J, Murphy MB, Ramirez DL, Soliman PT, Sood AK, Meric-Bernstam F. Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations. ESMO Open 10(12):105895, 2025. e-Pub 2025. PMID: 41223631.
13. Ileana Dumbrava, EE, Ileana Dumbrava, EE, Péloquin, S, Péloquin, S, Augustyniak, M, Augustyniak, M, Vu, J, Vu, J, Kuo, EY, Kuo, EY, Lazure, P, Lazure, P, Pasia, M, Pasia, M, Rivera, S, Rivera, S, Rodriguez, K, Rodriguez, K, Subbiah, V, Subbiah, V, Murray, S, Murray, S. A performance and quality improvement intervention integrating molecular testing to support personalized cancer care in lung and thyroid cancers 21:260, 2025. e-Pub 2025.
14. Dumbrava EE, Stinchcombe TE, Gounder M, Cote GM, Hanna GJ, Sumrall B, Wise-Draper TM, Kanaan M, Duffy S, Sumey C, Cobb P, Forbes A, Beckmann AG, Schadt EE, Ku N, Tirunagaru VG, Singh K, Pei X, Xu F, Doebele RC, Chen C. Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53. Clin Cancer Res 31(20):4255-4264, 2025. e-Pub 2025. PMID: 40788172.
15. George GC, Piha-Paul SA, Rodon Ahnert J, Dumbrava EE, Tsimberidou AM, Appleton G, Yap TA, Meric-Bernstam F, Hong DS. Dietary links with symptoms in early-phase immune checkpoint combinations trials. JCO Oncol Pract 21(11):341, 2025. e-Pub 2025.
16. Schram AM, Takebe N, Chen A, Zhou Q, Iasonos A, Silber J, Reynolds M, Hussain S, Gavriliuc M, Smyth LM, Garrison D, Dumbrava EE. A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. ESMO Open 10(9):105569, 2025. e-Pub 2025. PMID: 40939237.
17. Schram AM, Fellous M, LeDuke K, Schmid A, Dumbrava EE. PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation. Future Oncol 21(24):1-8, 2025. e-Pub 2025. PMID: 40932470.
18. Braganca Xavier C, Andersen CR, Lim J, Slade JH, Bean SA, Kang L, Le H, Tsimberidou AM, Naing A, Hong DS, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit. Cancer Res Commun 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
19. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
20. Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon Ahnert J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy RK, Valero V, Mouabbi JA, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
21. Michel L, Jimeno A, Sukari A, Beck JT, Chiu J, Ahern E, Hilton J, Even C, Zanetta S, Mekan S, Patel J, Wu T, Dumbrava EE. Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31(5):832-838, 2025. e-Pub 2025. PMID: 39665770.
22. Piha-Paul SA, Tseng C, Tran HT, Naing A, Dumbrava EE, Karp DD, Rodon J, Yap TA, Raghav KP, Damodaran S, Le X, Soliman PT, Lim J, Meric-Bernstam F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2):104136, 2025. e-Pub 2025. PMID: 39908697.
23. Stein MN, Dumbrava EE, Teply BA, Gergis U, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont C, Senesac JH, Bayle JH, Scripture CD, Chatwal M, Bilen MA, Stadler WM, Becerra CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer. Nature communications 15(1):10743, 2024. e-Pub 2024. PMID: 39737899.
24. Holla V, Kahle M, Kim SH, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Mills Shaw KR, Karp DD, Meric-Bernstam F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol 8:e2400419, 2024. e-Pub 2024. PMID: 39576951.
25. Tao DL, Nardo M, Leung CH, Lin HY, Kang L, Le H, Dumbrava EE, Hong DS. Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors. JAMA Network Open 7(11), 2024. e-Pub 2024. PMID: 39585697.
26. Chang JY, Xu X, Shroff G, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer 12(10):e009975, 2024. e-Pub 2024. PMID: 39384194.
27. Mohamed YI, Lee SS, Demir T, Chamseddine SM, Hu ZI, Xiao L, Elsayes KM, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, Lapelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan MM, Amin HM, Kaseb A. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomarkers 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
28. Tang C, Hartley G, Couillault CA, Yuan Y, Lin Y, Nicholas C, Srinivasamani A, Dai J, Dumbrava EEI, Fu S, Karp DD, Naing A, Piha-Paul SA, Rodon Ahnert J, Pant S, Subbiah V, Yap T, Tsimberidou AM, Guerrero PA, Dhebat S, Proia T, Curran M, Hong DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncol 3(1), 2024. e-Pub 2024. PMID: 39886125.
29. Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol 42(29):3421-3429, 2024. e-Pub 2024. PMID: 39083724.
30. Gouda MA, Shunyakova J, Naing A, Dumbrava E, Hong DS, Yuan Y, Yang P, Myers AL, Liang Y, Peng J, Karp DD, Tsimberidou AM, Rodon Ahnert J, Yap TA, Piha-Paul SA, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. e-Pub 2024. PMID: 38914452.
31. Torrado, C, Brink, AL, Gouda, M, Kang, L, Osburn, JA, Patterson, CJ, Charles, S, Poullard, A, Urschel, G, Ileana Dumbrava, EE, Karp, DD, Naing, A, Piha-Paul, SA, Pohlmann, PR, Rodon Ahnert, J, Tsimberidou, AM, Yap, TA, Hong, DS, Meric-Bernstam, F, Fu, S. Telehealth consultations and recruitment trends in clinical trials 42(16):1635, 2024. e-Pub 2024.
32. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
33. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
34. Nowlen, CJ, Daniels, MS, Uzunparmak, B, Dumbrava, EE, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
35. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun 4(2):378-387, 2024. e-Pub 2024. PMID: 38126764.
36. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
37. Chénard-Poirier, M, Almhanna, K, Lim, DT, El-Khoueiry, AB, Samol, J, Ryoo, BY, Yong Hong, J, Meng, R, Abbadessa, G, Masciari, S, Kefsi, A, Zhang, Y, Guillemin-Paveau, H, Pasquier, B, Lépine, L, Ileana Dumbrava, EE. Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors 42(16):2579, 2024. e-Pub 2024.
38. Schlechter, BL, Ileana Dumbrava, EE, George, MA, Saibil, SD, Butler, M, Giordano, A, Surana, R, Liao, CY, Weiss, J, Pieke, B, Gavriliuc, M, Lichtenstein, E, Apostolopoulou, M, Burke, C, Qureshi, B, Adib, DR, Olson, DJ. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors 42(3), 2024. e-Pub 2024.
39. Gouda, M, Lin, HY, Kang, L, Le, H, Ileana Dumbrava, EE, Fu, S, Karp, DD, Tsimberidou, AM, Naing, A, Piha-Paul, SA, Pohlmann, PR, Ahnert, JR, Yap, TA, Meric-Bernstam, F, Hong, DS. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors 42(16):3099, 2024. e-Pub 2024.
40. Tao, DL, Nardo, M, Leung, CH, Lin, HY, Kang, L, Le, H, Ileana Dumbrava, EE, Hong, DS. The role of obesity on outcomes of adoptive cellular therapy in solid tumors 42(16), 2024. e-Pub 2024.
41. Ileana Dumbrava, EE, Sohal, D, Olson, DJ, Saibil, SD, Urgelles, A, Apostolopoulou, M, Mueller, A, Moss, KM, Adib, DR, Schlechter, BL, Iqbal, S. First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors 42(3):TPS419-TPS419, 2024. e-Pub 2024.
42. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
43. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res 29(21):4385-4398, 2023. e-Pub 2023. PMID: 37279095.
44. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther 22(8):976-984, 2023. e-Pub 2023. PMID: 37339271.
45. Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. J Immunother Precis Oncol 6(3):158-161, 2023. e-Pub 2023. PMID: 37637237.
46. Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer 9(1):66, 2023. e-Pub 2023. PMID: 37567892.
47. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, Moore JA, Yilmaz B, Ogbonna DC, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton D, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale PR, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
48. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol 41(9):1725-1734, 2023. e-Pub 2023. PMID: 36469840.
49. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
50. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
51. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open 7(5):100573, 2022. e-Pub 2022. PMID: 36084396.
52. Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, Dumbrava EE. Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. J Adv Pract Oncol 13(7):664-672, 2022. e-Pub 2022. PMID: 36199491.
53. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
54. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
55. Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol 12:818679, 2022. e-Pub 2022. PMID: 35372008.
56. Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients with Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol 6:e2100456, 2022. e-Pub 2022. PMID: 35138920.
57. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
58. Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
59. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava El, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 27(11):3050-3060, 2021. e-Pub 2021. PMID: 33771853.
60. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
61. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res 23(1):29, 2021. e-Pub 2021. PMID: 33663585.
62. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2):e000931, 2020. e-Pub 2020. PMID: 33097611.
63. Marcelo-Lewis KL, Moorthy S, Ileana-Dumbrava E. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. J Immunother Precis Oncol 3(3):121-127, 2020. e-Pub 2020. PMID: 35663256.
64. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9:7, 2020. e-Pub 2020. PMID: 32337094.
65. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
66. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget 11(No.11):961-981, 2020. e-Pub 2020. PMID: 32215185.
67. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw K, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 3:1-12, 2019. e-Pub 2019. PMID: 32923865.
68. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget 10(49):5011-5019, 2019. e-Pub 2019. PMID: 31489111.
69. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 31517177.
70. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2019. PMID: 30442682.
71. Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy. J Immunother 41(7):336-339, 2018. e-Pub 2018. PMID: 29787423.
72. Dumbrava EI, Alfattal R, Miller VA, Tsimberidou AM. Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31123723.
73. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):685-690, 2018. e-Pub 2018. PMID: 29792354.
74. Dumbrava EI, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. JAMA Oncol 4(8):1118-1119, 2018. e-Pub 2018. PMID: 29801033.
75. Kurnit K, Dumbrava EEI, Litzenburger B, Khotskaya Y, Johnson A, Yap T, Rodon J, Zeng J, Shufean A, Bailey A, Sánchez N, Holla V, Mendelsohn J, Shaw K, Bernstam E, Mills G, Meric-Bernstam F. Precision oncology decision support: current approaches and strategies for the future. Clin Cancer Res 24(12):2719-2731, 2018. e-Pub 2018. PMID: 29420224.
76. Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy- leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud 4(2):1-9, 2018. e-Pub 2018. PMID: 29212833.
77. Ileana-Dumbrava E, Subbiah V. Autoimmune hypophysitis. Lancet Oncol 19(2):e123, 2018. e-Pub 2018. PMID: 29413466.
78. Daniels M, Wathoo C, Brusco L, Lu K, Shaw K, Dumbrava EEI, Arun B, Strong L, Litton J, Eterovic AK, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active Disclosure of Secondary Germline Findings to Deceased Research Participants’ Personal Representatives: Process and Outcomes. JCO Precis Oncol 1, 2017. e-Pub 2017. PMID: 31552380.
79. Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer 81:81-89, 2017. e-Pub 2017. PMID: 28618305.
80. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7(6):586-595, 2017. e-Pub 2017. PMID: 28365644.
81. Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs 28(5):540-545, 2017. e-Pub 2017. PMID: 28225458.
82. Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res 22(12):2960-8, 2016. e-Pub 2016. PMID: 26758560.
83. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). Eur J Cancer 59:79-89, 2016. e-Pub 2016. PMID: 27017289.
84. Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Ann Oncol 27(2):344-52, 2016. e-Pub 2016. PMID: 26598538.
85. Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 51(17):2570-7, 2015. e-Pub 2015. PMID: 26278649.
86. Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer 51(14):1946-52, 2015. e-Pub 2015. PMID: 26208462.
87. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer 89(3):306-10, 2015. e-Pub 2015. PMID: 26160757.
88. Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K. Who dies from prostate cancer?. Prostate Cancer Prostatic Dis 17(4):348-52, 2014. e-Pub 2014. PMID: 25311767.
89. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7):1807-12, 2013. e-Pub 2013. PMID: 23576708.
90. Ileana E, Greillier L, Moutardier V, Barlesi F. Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon?. Lung Cancer 70(2):221-2, 2010. e-Pub 2010. PMID: 20828859.
91. Legodec J, Maldonado F, Ileana E, Greillier L, Dutau H, Astoul P. Pathologie pleurale. Revue des Maladies Respiratoires 2(Suppl 1):106-120, 2010. e-Pub 2010.

Review Articles

1. Adesoye T, Dumbrava EE, Raghav KS, Sahin AA, Chen H, Lee SS, Javle M, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F. Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. Clin Cancer Res 32(2):260-290, 2026. e-Pub 2026. PMID: 41283902.
2. Dumbrava EE, Frej KH, Sharon E, Tawbi H. Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. Annual Review of Medicine 76(1):189-205, 2025. e-Pub 2025. PMID: 39656959.
3. Koksoy, AA, Uzunparmak, B, Raso, G, Perez, R, Wang, L, Yildirim, O, Abbadessa, G, Masciari, S, Barrientos Toro, E, Batra, H, Parra Cuentas, ER, Rizvi, YQ, Lazcano Segura, RN, Ding, Q, Champiat, S, Meric-Bernstam, F, Haymaker, CL, Dumbrava, EE. Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer 43(16_suppl):1037, 2025. e-Pub 2025.
4. Sofianidi A, Dumbrava EE, Syrigos KN, Nasrazadani A. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets. Cancers (Basel) 16(6), 2024. e-Pub 2024. PMID: 38539474.
5. Bhamidipati, D, Haro-Silerio, JI, Ileana Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Johnson, A, Lee, MS, Dasari, NV, Raghav, KS, Morris, VK, Overman, MJ, Kopetz, S, Meric-Bernstam, F, Yap, TA. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations 42:134, 2024. e-Pub 2024.
6. Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. Cancer Immunol Res 9(11):1252-1261, 2021. e-Pub 2021. PMID: 34728535.
7. Ileana EE, Wistuba II, Izzo JG. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. Cancer J 21(5):413-24, 2015. e-Pub 2015. PMID: 26389767.
8. Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR Signaling in Cancer. Clin Cancer Res 21(12):2684-94, 2015. e-Pub 2015. PMID: 26078430.
9. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 9(2):144-53, 2014. e-Pub 2014. PMID: 24419410.
10. Ileana E, Champiat S, Soria JC. Immune-checkpoints: the new anti-cancer immunotherapies. Bull Cancer 100(6):601-10, 2013. e-Pub 2013. PMID: 23735730.

Other Articles

1. Dumbrava EE, Hanna GJ, Cote GM, et al A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2), 2022.

Editorials

1. Ileana-Dumbrava EE. Unraveling the mysteries of microsatellite instability. Sci Transl Med 13(575), 2021.
2. Ileana-Dumbrava E. Early stage EGFR-mutated lung cancer gets a targeted treatment. Sci Transl Med 12(567), 2020.
3. Ileana-Dumbrava E. PARP inhibitors unleash the antitumor immune response. Sci Transl Med 12(559), 2020.
4. Ileana-Dumbrava E. Do dendritic cells hold the key to regulating cancer antitumor immunity?. Sci Transl Med 12(551), 2020.
5. Ileana-Dumbrava E. COVID-19 and Cancer: The bad and the ugly. Sci Transl Med 12(543), 2020.
6. Ileana-Dumbrava E. Boosting immune responses against early breast cancer. Sci Transl Med 12(535), 2020.
7. Ileana Dumbrava EE, Mills GB, Yap TA. Targeting gamma secretase: has progress moved up a notch?. Ann Oncol 29(9):1889-1891, 2018. PMID: 30084907.

Abstracts

1. Chakraborty A, Venturini J, Baysal MA, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with cell cycle alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3149, 2026. e-Pub 2026.
2. Tsimberidou AM, Venturini J, Baysal MA, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F. Clinical outcomes of patients with PI3K pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3150, 2026. e-Pub 2026.
3. Surana R, Schoenfeld AJ, Kamgar M, Dumbrava EE, Paulson AS, Becerra CR, Leidner RS, Boland PM, Hecht JR, Kundrana MN, Zhang JY, Pelster M, Yan Y, Liao Y, Shin Y, Paz-Chang H, Whangbo J, Ahrorov A, Cohen S, Fakih M. Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors. ASCO Annual Meeting 44(16_suppl), 2026. e-Pub 2026.
4. Pilie PG, Ozirmak Lermi N, Lubo I, Khan K, Lu W, Roemer B, Salvatierra M, Jiang M, Solis LM, Isgandarova S, Armador Molina JC, Lu H, Brown CV, Szymonowicz KA, Dumbrava EE, Ngoi N, Chen K, Meric-Bernstam F, Haymaker CL, Yap TA. Phase 1/2 trial of ATR Inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDE) gene alterations: Tumor microenvironment - mediated pathways of resistance from correlatieve data. ASCO Annual Meeting 44(16_Suppl):3141, 2026. e-Pub 2026.
5. Venturini J, Baysal MA, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with TP53 pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3152, 2026. e-Pub 2026.
6. Lemech CR, Wei J, Chawla SP, Dumbrava EE, Sharma S, Kim SY, Schmidt AL, Bishnoi SK, Gundala S, Rastogi S, Prabash K, Jain MM, Inamdar SP, Chimote G, Sreenivasan J. A phase 1, mulitcenter, open-label, dose-escalation and expension study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors. ASCO Annual Meeting 44(16_suppl):TPS3161, 2026. e-Pub 2026.
7. Derbala MH, Haymaker CL, Morris II VK, Javle MM, How JA, A-M C, Gurses SA, Stephen B, T-Y T, Champiat S, Rodon Ahnert J, Yap TA, Dumbrava EE, Piha-Paul SA, Tsimberidou AM, Fu S, Hong DS, Ashtamker N, Meric-Bernstam F, Naing A. Biomarker Study of BND-22 in combination with cemiplimab in solid tumors. ASCO Annual Meeting 44(16_suppl):TPS2676, 2026. e-Pub 2026.
8. Akcakanat A, Dumbrava EE, Evans KW, Zhang R, Zhao M, Kennon A, Zheng X, Scott SM, Yuca E, Raso G, Kong EK, Rizvi Y, Hong D, Poyurovsky MV, Lozano G, Korkut A, Meric-Bernstam F. Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers. AACR Annual Meeting 86(7), 2026. e-Pub 2026.
9. Reddy T, Lei K, Le H, Damodaran S, Singh Ragav KP, Kopetz S, Rodon Ahnert J, Dumbrava EE, Yap TA, Williams S, Routbort MJ, Patel KP, Meric-Bernstam F. Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics. AACR Annual Meeting 86(7_Suppl):2967, 2026. e-Pub 2026.
10. Ahmed J, Stephan B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Yan H, Lim JT, Klekers AR, Le H, Kang L, Xu M, Tan HN, Champiat S, Tin-Yun T, Dumbrava EE, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Hong DS, Meric-Bernstam F, Bhosale PR, Naing A. Impact of severe liver metastases on clinical response to immunotherapy in solid tumors. AACR Annual Meeting 86(8_suppl):LB429, 2026. e-Pub 2026.
11. Mirallas O, Marin D, Chen H, Pohlmann P, Lim B, Altan M, Hussain S, Kennon A, Daher M, Gavriliuc M, Basar R, W-L W, Yuan Y, Kebriaei P, Shpall EJ, Rodon J, Hong DS, Meric-Bernstam F, Rezvani K, Dumbrava EE. Phase I study of TROP2 CAR engineered IL-15-transduced cord blood-derived NK cells in advanced solid tumors (TROPIKANA). AACR Annual Meeting 86(8_suppl):CT294, 2026. e-Pub 2026.
12. Chandana SR, Kelley RK, Fin RS, Dumbrava EE, Ikeda M, Hamm JT, Grewal JS, Gutierrez M, Maruki Y, Nakajima TE, Ikoma T, M Weinstein M, Mekan SF, Abou-Alfa GK. A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC). 2026 ASCO Gastrointestinal Cancers Symposium 44(2 suppl):TPS608, 2026. e-Pub 2026.
13. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
14. Papadopoulos K, Cecchini M, Lopez JS, Jäger D, Chung KY, Platten M, Prinz F, Ishii Y, Schaer D, Gutcher I, Leder G, Pencheva R, Wagener T, Scheerans C, Zieschang C, Wagner A, Stamatelos S, Dumbrava E. Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
15. Cabanas EG, Fontana E, Oberoi HK, Uboha NV, Dumbrava EE, Calvo E, Curigliano G, Davar D, Keenan BK, Lam VK, manda S, Mehta A, Monchom A, Moskowitz A, Paluri R, Ribrag V, Richards D, Siu L, Swiecicki P, Wise-Draper T, Zain J, Forero-Torres A, Xu P, Ansel S. Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
16. Holla V, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Shaw KR, Karp DD, Meric-Bernstam F. Genomic alterations in DNA mismatch repair (dMMR). Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
17. Dumbrava EE, Olson D, Saibil S, Pieke B, George MA, Bouvier R, Gavriliuc M, Gruber K, Moss K, Ternus N, Apostolopoulou M, Adib D, Schlechter BL. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
18. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
19. Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
20. Rasco D, Dumbrava EE, Sharma MR, Shepard D, Vaena D, Fleming G, Chmielowski B, Hamilton EP, Sullivan RJ, Papadopoulos KP, Patnaik A, fOphir E, Cojocaro G, Bohac C, Adewoye AH, Patel MR, Overman MJ. COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 10(suppl 2):p. A689, 2022. e-Pub 2022.
21. Henry J, Oh D, Eskew JD, Baranda J, Rodriguez Rivera II, Dumbrava EE, Cohen E, Belani R, McCaigue J, Shedlock DJ, Coronella J, Martin CE, Namini H, Murphy A, Ostertag EM. Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers. J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 10(suppl 2):p. A760, 2022. e-Pub 2022.
22. Schlechter BL, Olson D, Saibil S, George M, Bouvier R, McKinley J, Pieke B, Geisburger J, Ternus NJ, Moss K, Adib D, Dumbrava EE. A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors. J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 10(suppl 2):p. A791, 2022. e-Pub 2022.
23. Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. Eur J Cancer: Abstracts, 34th EORTC-NCI-AACR Symposium 174(suppl 1):p. S7, 2022. e-Pub 2022.
24. Hamid O, Sato T, Davar D, Callahan M, Thistlethwaite F, Aljumaily R, Johnson M, H-T A, Dumbrava EE, Izar B, Chen HA, Marshall S, Yuan Y, Deo M, Stanhope S, Collins L, Mundy R, Abdullah S, Lopez J. Results from Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Ann Oncol: Proceedings of the 2022 ESMO Congress 33(Issue S7):p. S875, 2022. e-Pub 2022.
25. Ngoi NY, Lin H, Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. Ann Oncol: Proceedings of the 2022 ESMO Congress 33(Issue S7):p. S761-S762, 2022. e-Pub 2022.
26. Schlechter BL, Dumbrava EE, Olson D, Saibil S, Pieke B, Bouvier R, Moss K, Turnus N, Bader A, Adib D. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Ann Oncol: Proceedings of the 2022 ESMO Congress 33(Issue S7):p.S896, 2022. e-Pub 2022.
27. Dumbrava EE, Hanna GJ, Cote GM, Stinchcombe TE, Johnson ML, Chen CT, Devarakonda SHK, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
28. DiPeri TD, Kong K, Karp DD, Ajani JA, Pant S, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 expression and/or amplification on repeat testing. Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
29. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 40(suppl 16):3013, 2022. e-Pub 2022.
30. Zhao M, DiPeri TP, Raso G, Rizvi YQ, Zheng X, Evans K, Akcakanat A, Yang F, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan. Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
31. Dumbrava EE, Olson D, Schlechter BL, Saibil S, Rill D, Bader A, Adib D, Bishop M. A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2). Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
32. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
33. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
34. Dumbrava EE, Johnson ML, Tolcher AW, Shapiro G, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Parikh AR, Munster PN, Daly E, De Leon L, Khaddar M, LeDuke K, Robell K, Sheehan LI, St Louis M, Wiebesiek A, Alland L, Schram AM. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
35. Dumbrava EE, Burton EM, Subudhi SK, Milton DR, Aparicio A, Yap TA, Naing A, Gettys Corn P, Pilie PG, Zurita AJ, Wang J, Navroze Amaria R, McQuade JL, Glitza IC, Lazar AJ, Meric-Bernstam F, Logothetis C, Davies MA, Hwu P, Tawbi HA. Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
36. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
37. Dumbrava EE, Hanna GJ, Cote GM, Stinchombe T, Johnson ML, Chen C, Devarakonda S, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
38. McKean M, Dumbrava EE, Hamid O, Merriam P, Mettu NB, Call JA, Kapoun AM, Lucas J, Seetharam M, Vaishampayan UN, Veroha SJ, Krishnan S, George AJ. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
39. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
40. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
41. Davar D, Ribrag V, Sarkozy C, Garralda E, Kumar Oberoi H, Mehta A, Curigliano G, Belli C, Zain J, Herrera A, Sanborn R, Dumbrava E Forero-Torres A, Ansell S. Phase 1 Study Of SEA-TGT, A Human, Nonfucosylated Anti-Tigit Monoclonal Antibody With Enhanced Immune-Effector Function, In Patients With Advanced Malignancies (Sgntgt-001, Trial In Progress). SITC Annual Meeting 9(suppl 2):474, 2021. e-Pub 2021.
42. Burton E, Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. ESMO Congress 32(suppl 5):S899, 2021. e-Pub 2021.
43. Park H, Shapiro G, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Hickman D, Gallacher PD, Attar EC, Awad MM, Das S, Dumbrava EE. Phase 1/2 study of Eprenetapopt (APR-246) in Combination with Pembrolizumab in Patients with Solid Tumor Malignancies. ESMO Congress 32(Suppl 5):S586, 2021. e-Pub 2021.
44. Moyers J, Nguyen D, Hong DS, Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 32(suppl 5):838, 2021. e-Pub 2021.
45. Vaena DA, Fleming GF, Chmielowski B, Sharma M, Hamilton EP, Sullivan RJ, Shepard DR, Papadopoulos KP, Patnaik A, ElNaggar A, Adewoye AH, Smith R, Lim EA, Dumbrava EE, Rasco DW. COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716). ASCO Annual Meeting 39(suppl 15):2504, 2021. e-Pub 2021.
46. Sharma M, Carvajal RD, Hanna GJ, Li BT, Moore KN, Pegram MD, Rasco DW, Spira AI, Alonso M, Fang L, Husain A, Perez EA, Dumbrava EE. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. ASCO Annual Meeting 39(suppl 15):2549, 2021. e-Pub 2021.
47. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3001, 2021. e-Pub 2021.
48. Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3090, 2021. e-Pub 2021.
49. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EE, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes. ASCO Annual Meeting 39(suppl 5):3138, 2021. e-Pub 2021.
50. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. ASCO Annual Meeting 39(suppl 15):3017, 2021. e-Pub 2021.
51. Dumbrava EE, Dougan ML, Gupta S, Cappelli L, Katsumoto TR, Rahma OE, Painter J, Wang Y, Suarez-Almazor ME, Reid P, Wesley SF, Hafler DA, Bingham CO, Warner BM, Chung L, Ott PA, Kluger HM, Khosroshahi A, Tawbi HA, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). ASCO Annual Meeting 39(15 suppl):TPS2676, 2021. e-Pub 2021.
52. Robert F, Dumbrava EE, Xing Y, Mills E, Freddo JL, Theuer CP, Adams BJ, Lawrence J, Trigeiro AA, Xu C, Meng Y, Lee L, Zhao Y, Wang J, Shen HJ, Gordon MS. Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. ASCO Annual Meeting 39(supple 15):2511, 2021. e-Pub 2021.
53. Dumbrava EE, Shapiro G, Bendell JC, Yap TA, Jeselsohn R, Lepley DM, Hurley S, Lin KK, Liao M, Habeck J, Enke A, Hamilton EP. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3102, 2021. e-Pub 2021.
54. Park H, Shapiro G, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Hickman D, Gallacher PD, Attar EC, Awad MM, Das S, Dumbrava EE. Phase 1/2 study of Eprenetapopt (APR-246) in Combination with Pembrolizumab in Patients with Solid Tumor Malignancies. ASCO Annual Meeting 32(suppl 5):S586, 2021. e-Pub 2021.
55. Govindan R, Townsend AR, Miller KD, Mehmi I, Kuboki Y, Dumbrava EE, Hamilton EP, Vuu I, Rasmussen E, Mileshkin LR, Genta S, Iwata H, Adams S, Fujii H, Chawla SP. Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. ASCO Annual Meeting 39(suppl 15):TPS5600, 2021. e-Pub 2021.
56. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. AACR Annual Meeting 81(suppl 13):974, 2021. e-Pub 2021.
57. Sharma MR, Carvajal RD, Catenacci D, Emens LA, Hanna GJ, Juric D, Y-K K, Lee J, K-W L, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Heeke AL, Wang D, Garbo L, Manda S, Sachdev J, Ackerman SE, LeBlanc H, Dornan D, Kowaneta M, Alonso MN, Husain A, Perez EA, Dumbrava EE. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors. AACR Annual Meeting 81(suppl 13):CT218, 2021. e-Pub 2021.
58. Dumbrava EE, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Dejan Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. San Antonio Breast Cancer Symposium 81(suppl 4), 2020. e-Pub 2020.
59. Hong DS, Butler MO, Russell Pachynski R, Sullivan RJ, Kebriaei P, Boross-Harmer S, Frigault MJ, Dumbrava E, Sauer A, Brophy F, Navenot JM, Fayngerts S, Bai J, Norry E, Fracasso PG. Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. SITC Annual Meeting 8(Suppl 3), 2020. e-Pub 2020.
60. Sharma MR, Ileana Dumbrava E, Carvajal RD, Catenacci DV, Emens LA, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore KN, Pegram MD, Pohlmann PR, Rasco D, Spira AI, Tan A, Wang D, Ackerman SE, LeBlanc HN, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. SITC Annual Meeting 8(Suppl 3), 2020. e-Pub 2020.
61. Fu S, Hong D, Fogelman D, Shaikh F, Dupont-Roettger D, Bisdas S, Ileana Dumbrava EE, Piha-Paul S, Liu S, Dugourd D, Yamamura Y. A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours. ESMO Congress 31(Supplement 4):S462-S504, 2020. e-Pub 2020.
62. Yap TA, Hamilton EP, Bauer TM, Ileana Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Wride K, Giordano H, Shapiro G. Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131). ESMO Congress 31(Supplement 4):S462-S504, 2020. e-Pub 2020.
63. Dumbrava EE, Suarez-Almazor ME, Painter J, Johanns T, Dougan ML, Cappelli L, Bingham CO, Wang Y, Gupta S, Warner BM, Rahma OE, Naidoo J, Ott PA, Hafler DA, Kluger HM, Khosroshahi A, Katsumoto TR, Kummar S, Sharon E, Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). ASCO Annual Meeting 38(suppl 15):TPS3158, 2020. e-Pub 2020.
64. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Dumbrava EE, Rodon Ahnert J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang W, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. ASCO Annual Meeting 38(suppl 15):3629, 2020. e-Pub 2020.
65. Subbiah IM, Buzdar A, Dumbrava EE, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. ASCO Annual Meeting 38(15):12044, 2020. e-Pub 2020.
66. Piha-Paul SA, Dumbrava EE, Janku F, Karp DD, Meric-Bernstam F, Rodon J, Ngo B, Peng P, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors. ASCO Annual Meeting 80(16):3011, 2020. e-Pub 2020.
67. Dumbrava E, Suarez-Almazor M, Painter J, Johanns TM, Dougan ML, Cappelli L, Wang Y, Bingham C, Gupta S, Warner BM, Rahma O, Naidoo J, Ott PA, Hafler DA, Kluger H, Khosroshahi A, Naqash R, Chung L, Katsumoto TR, Kummar S, Tawbi H, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). AACR Annual Meeting 80(16):CT249, 2020. e-Pub 2020.
68. Sullivan R, Rasco D, Lim E, Sharma M, Shepard D, Patnaik A, Hamilton E, Fleming G, Papadopoulos K, ElNaggar A, Adewoye AH, Chmielowski B, Dumbrava E, Vaena D. COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors. AACR Annual Meeting 80(16):CT031, 2020. e-Pub 2020.
69. Hegde A, Jayaprakash P, Sumner E, Nguyen D, Zain H, Piha-Paul SA, Karp D, Rodon J, Pant S, MBBS, Fu S, Dumbrava EI, Yap TA, PhD MD, Subbiah V, Bhosale P, Higgins JP, Williams ET, Wilson TF, Meric-Bernstam F, Curran MA, Hong DS. A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. SITC Annual Meeting, 2019. e-Pub 2019.
70. Dumbrava E, Fleming G, Hamilton EP, Sullivan RJ, Patnaik A, Papadopoulos KP, ElNaggar A, Hunter J, Olweny J, Adewoye AH, Adewoye AH, Chmielowski B, Shepard D, Sharma MR, Lim E, Vaena D, Rasco D. Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. SITC Annual Meeting, 2019. e-Pub 2019.
71. Dumbrava EI, Fleming GF, Hamilton EP, Sullivan RJ, Patnaik A, Papadopoulos KP, ElNaggar A, Hunter J, Olweny J, Adewoye AH, Chmielowski B, Shepard D, Sharma MR, Lim E, Vaena D, Rasco D. Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. SITC Annual Meeting, 2019. e-Pub 2019.
72. Pairawan S, Evans K, Kopetz S, Akcakanat A, Zhao M, Tapia C, Busaidy N, Dumbrava E, Meric-Bernstam F. The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019. e-Pub 2019.
73. Coyne GO, Yap T, Moore N, Mittra A, Takebe N, Juwara L, Khan S, Dumbrava E, Streicher H, Piekarz R, Sharon E, Meric-Bernstam F, Parchment R, Navas T, Fung K, Mitchell J, Fino K, Montez S, Doyle A, Rubinstein L, Doroshow J, Chen A. Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019. e-Pub 2019.
74. Naing A, Meric-Bernstam F, Karp D, Rodon JA, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Dumbrava EE, Colen RR, Hess KR, Campbell MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in Advanced Rare Cancers. ESMO Congress 30(suppl 5):v516-v517, 2019. e-Pub 2019.
75. Meric-Bernstam F, Somaiah N, DuBois SG, Dumbrava EE, Shapiro GI, Patel MR, Goel S, Bauer T, Pinchasik D, Annis A, Aivado M, Vukovic V, Saleh M. A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification. ESMO Congress 30(suppl 5):v179-v180, 2019. e-Pub 2019.
76. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah S, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. ASCO Annual Meeting 37(15 suppl):3014, 2019. e-Pub 2019.
77. Naing A, Ileana Dumbrava E, Murthy R, Meric-Bernstam F, Fox A, Krige D, Carter J, Champion B, Cockle P, Koetz B, McElwaine-Johnn H. A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). ASCO Annual Meeting 37(15 suppl):TPS2668, 2019. e-Pub 2019.
78. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EE, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer, 2019. e-Pub 2019. PMID: 32188704.
79. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Ileana Dumbrava E, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. AACR Special Conference on Targeting PI3K/mTOR Signaling, 2018. e-Pub 2018.
80. Ileana Dumbrava EE, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder S, Koeing K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. AACR Special Conference on Targeting PI3K/mTOR Signaling, 2018. e-Pub 2018.
81. Ileana Dumbrava E, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp D, Fu S, Naing A, Tsimberidou AM, Moulder S, Koenig K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. AACR Special Conference on Targeting PI3K/mTOR Signaling, 2018. e-Pub 2018.
82. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Ileana Dumbrava E, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. San Antonio Breast Cancer Symposium Volume 79(4 Suppl):pp. P6-21-04, 2018. e-Pub 2018.
83. Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, J-G R, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Ileana Dumbrava E, Aivado M, Meric-Bernstam F. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. San Antonio Breast Cancer Symposium 79(Suppl 4):pp. P6-20-11, 2018. e-Pub 2018.
84. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong D, Rodon J, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 17(1 Suppl):#A167, 2017. e-Pub 2017.
85. Ileana Dumbrava EE, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Routbort M, Piha-Paul S, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. ASCO Annual Meeting 35(15 Suppl):#1524, 2017. e-Pub 2017.
86. Ileana Dumbrava E, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Piha-Paul S, Subbiah V, Hong DS, Woodman S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. ASCO Annual Meeting 35(15 Suppl):#11567, 2017. e-Pub 2017.
87. Shien K, Ruder D, Ileana E, Papadimitrakopoulou VA Frampton GM, Behrens C, Kalhor N, Lee JJ, Tang X, Herbst RS, Wistuba II, Izzo JG. Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis. Cancer Research 76(suppl 14):pp. 1144, 2016. e-Pub 2016.
88. Ileana E, Jovelet C, Le Deley MC, Massard C, Motté N, Hollebecque A, Boichard A, Ferté C, Postel-Vinay S, Rosellini S, Ngo-Camus M, De Baere T, Vielh P, Richon C, Laporte M, Gouissem S, Loriot Y, Bahleda R, Gazzah A, Varga A, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. Cancer Res 75(15 Suppl):#2401, 2015. e-Pub 2015.
89. Ileana E, Antoun S, Albiges L, Massard C, Di Palma M, Escudier B, Fizazi K, Loriot Y. Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol: Proceedings of the ASCO Annual Meeting 31(Suppl 15):#5088, 2013. e-Pub 2013.
90. Bianchini D, Loriot Y, Ileana E, Sandhu S, Pezaro C, Albiges L, Attard G, Fizazi K, de Bono JS, Massard C. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. Annals of Oncology 23(Suppl 9):#924P, 2012. e-Pub 2012.
91. Ileana E, Maldonado F, Astoul P. Where did my central line go? The pinch-off syndrome. Cancer Imaging 10(Suppl):#200, 2010. e-Pub 2010.
92. Ileana E, Diaconu B, Tantau M, Laugier R. Efficacy of endoscopic treatment in chronic pancreatitis assessed by Izbicki Score 9:#P-103, 2009. e-Pub 2009.

Book Chapters

1. Ileana-Dumbrava E. Targeting DNA Damage Response. Handbook of Targeted Cancer Therapy and Immunotherapy. In: Wolters Kluwer. 2nd, 2018.
2. Herold J, Ileana-Dumbrava E. PDGFR and targeting PDGFRA. In: Wolters Kluwer. 2nd, 2018.
3. Ileana-Dumbrava E. TIE receptors. In: Wolters Kluwer. 2nd, 2018.
4. Perkins A, Ileana-Dumbrava E. Targeting IGFR-1 and Insulin Receptor. In: Wolters Kluwer. 2nd, 2018.
5. Marcelo-Lewis K, Ileana-Dumbrava E. Management of Immune-Related Toxicities Handbook of Targeted Cancer Therapy. In: Wolters Kluwer. 2nd, 2018.
6. Perkins A, Ileana-Dumbrava E. Targeting TGFß/SMAD Pathway. In: Wolters Kluwer. 2nd, 2018.

Books (edited and written)

1. Ileana Dumbrava E. Section 3: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. Ed(s) 3rd Edition. Wolters Kluwer, 2022.
2. Ileana Dumbrava E. Section 2: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. Ed(s) 2nd Edition. Wolters Kluwer, 2018.

Web Publications

1. Heidi Ledford. Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments- (Interview with Dr. Dumbrava), 2026.
2. Nuria W Negrao. MDM2 Inhibition Marches on Across Cancer Settings- (Interview with Dr. Dumbrava), 2023.
3. Amorosi D. Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors- (Perspective from Dr. Dumbrava), 2021.
4. Devon Carter. Can immunotherapy treat cancer in patients with autoimmune diseases?- (Interview with Dr. Dumbrava), 2021.
5. Devon Carter. Monoclonal antibodies and cancer treatment: What to know? (Interview with Dr. Dumbrava), 2020.